home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2987.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
2KB
|
37 lines
Document 2987
DOCN M94A2987
TI Daunoxome-phase II trial for epidemic Kaposi's sarcoma (EKS).
DT 9412
AU Wernz JC; Taubes B; Friedberg A; NYU Kaplan Cancer Center, NY.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):18 (abstract no. 046B). Unique
Identifier : AIDSLINE ICA10/94369588
AB In January 1993 accrual began at NYU Medical Center using the
investigational drug Daunoxome for previously treated patients with
progressive EKS. As of February 18, 1994 42 patients had been entered on
study. Daunoxome is a combination of daunorubicin and a phospholipid
vesicle carrier (liposome) specifically developed for its tumor
targeting abilities. The drug appears to be most active in reducing the
EKS associated edema which frequently is a major problem in advanced
EKS. The drug is given in the outpatient setting every two weeks at a
dose of 40mg/m2. If there is no response after two cycles, the dose is
increased to 60mg/m2. Response was graded according to the ACTG response
criteria. 14/42 patients achieved a partial response (PR) and 28/42
remained with stable disease (SD). 10/14 patients continue with PR. The
median duration of response at 40mg/m2 is 9+ weeks (2-44+) and at
60mg/m2 is 7.5+ weeks (4-52+). 20 patients remain on study. Neutropenia
is a dose limiting toxicity; however, patients can be kept on schedule
with Neupogen support. There is essentially no alopecia and minimal
nausea. To this date there has been no evidence of cardiac toxicity.
Daunoxome is effective in advanced EKS in patients who have progressed
on previous chemotherapy and has a very high patient acceptance.
DE Daunorubicin/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Drug Carriers
Granulocyte Colony-Stimulating Factor/THERAPEUTIC USE Human
Lymphedema/DRUG THERAPY/ETIOLOGY Neutropenia/CHEMICALLY INDUCED
Recombinant Proteins/THERAPEUTIC USE Sarcoma,
Kaposi's/COMPLICATIONS/*DRUG THERAPY CLINICAL TRIAL CLINICAL TRIAL,
PHASE II MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).